000157757 001__ 157757
000157757 005__ 20230915092353.0
000157757 0247_ $$2doi$$a10.1093/brain/awaa413
000157757 0247_ $$2pmid$$apmid:33501939
000157757 0247_ $$2pmc$$apmc:PMC8041322
000157757 0247_ $$2ISSN$$a0006-8950
000157757 0247_ $$2ISSN$$a1460-2156
000157757 0247_ $$2altmetric$$aaltmetric:98955948
000157757 037__ $$aDZNE-2021-01214
000157757 041__ $$aEnglish
000157757 082__ $$a610
000157757 1001_ $$aNaasan, Georges$$b0
000157757 245__ $$aPsychosis in neurodegenerative disease: differential patterns of hallucination and delusion symptoms.
000157757 260__ $$aOxford$$bOxford Univ. Press$$c2021
000157757 3367_ $$2DRIVER$$aarticle
000157757 3367_ $$2DataCite$$aOutput Types/Journal article
000157757 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1632298773_31141
000157757 3367_ $$2BibTeX$$aARTICLE
000157757 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000157757 3367_ $$00$$2EndNote$$aJournal Article
000157757 520__ $$aAlthough psychosis is a defining feature of Lewy body disease, psychotic symptoms occur in a subset of patients with every major neurodegenerative disease. Few studies, however, have compared disease-related rates of psychosis prevalence in a large autopsy-based cohort, and it remains unclear how diseases differ with respect to the nature or content of the psychosis. We conducted a retrospective chart review of 372 patients with autopsy-confirmed neurodegenerative pathology: 111 with Alzheimer's disease, 59 with Lewy body disease and concomitant Alzheimer's disease, 133 with frontotemporal lobar degeneration (FTLD) with tau inclusions (including progressive supranuclear palsy, corticobasal degeneration or Pick's disease), and 69 with FTLD and TDP inclusions (FTLD-TDP, including types A-C). Psychosis content was classified by subtype, and the frequency of each subtype was compared among pathological diagnoses using logistic regression. A total of 111 of 372 patients had psychosis. Compared to other groups, patients with Lewy body disease/Alzheimer's disease pathology were significantly more likely to have hallucinations and were more likely to have more than one subtype of hallucination. Patients with Braak Parkinson stage 5-6 Lewy body disease were significantly more likely than those with no Lewy body disease to have visual hallucinations of misperception, peripheral hallucinations, hallucinations that moved, hallucinations of people/animals/objects, as well as delusions regarding a place and delusions of misidentification. The feeling of a presence occurred significantly more frequently in patients with Lewy body disease/Alzheimer's disease than all other pathologies. Patients with FTLD-TDP were significantly more likely to have delusions, and for the delusions to occur in the first 3 years of the disease, when compared to patients with Alzheimer's disease and FTLD-tau, though rates were not significantly greater than patients with Lewy body disease/Alzheimer's disease. Paranoia occurred more frequently in the FTLD-TDP and Lewy body disease/Alzheimer's disease categories compared to patients with Alzheimer's disease or FTLD-tau. Patients with FTLD-TDP pathology had delusions of misidentification as frequently as patients with Lewy body disease/Alzheimer's disease, and were significantly more likely to have self-elevating delusions such as grandiosity and erotomania compared to patients with other pathologies including FTLD-tau. These data show that the nature and content of psychosis can provide meaningful information about the underlying neurodegenerative pathology, emphasizing the importance of characterizing patients' psychoses for prediction of the neuropathological diagnosis, regardless of a patient's clinical syndrome.
000157757 536__ $$0G:(DE-HGF)POF4-352$$a352 - Disease Mechanisms (POF4-352)$$cPOF4-352$$fPOF IV$$x0
000157757 588__ $$aDataset connected to CrossRef, PubMed, , Journals: pub.dzne.de
000157757 650_7 $$2Other$$aLewy body disease
000157757 650_7 $$2Other$$aTDP-43
000157757 650_7 $$2Other$$afrontotemporal dementia
000157757 650_7 $$2Other$$apathology
000157757 650_7 $$2Other$$apsychosis
000157757 650_2 $$2MeSH$$aAged
000157757 650_2 $$2MeSH$$aDelusions: epidemiology
000157757 650_2 $$2MeSH$$aDelusions: etiology
000157757 650_2 $$2MeSH$$aFemale
000157757 650_2 $$2MeSH$$aHallucinations: epidemiology
000157757 650_2 $$2MeSH$$aHallucinations: etiology
000157757 650_2 $$2MeSH$$aHumans
000157757 650_2 $$2MeSH$$aMale
000157757 650_2 $$2MeSH$$aMiddle Aged
000157757 650_2 $$2MeSH$$aNeurodegenerative Diseases: complications
000157757 650_2 $$2MeSH$$aPrevalence
000157757 650_2 $$2MeSH$$aPsychotic Disorders: epidemiology
000157757 650_2 $$2MeSH$$aPsychotic Disorders: etiology
000157757 7001_ $$aShdo, Suzanne M$$b1
000157757 7001_ $$0P:(DE-2719)2812759$$aMorenas Rodriguez, Estrella$$b2$$udzne
000157757 7001_ $$aSpina, Salvatore$$b3
000157757 7001_ $$aGrinberg, Lea$$b4
000157757 7001_ $$aLopez, Lucia$$b5
000157757 7001_ $$aKarydas, Anna$$b6
000157757 7001_ $$aSeeley, William W$$b7
000157757 7001_ $$aMiller, Bruce L$$b8
000157757 7001_ $$aRankin, Katherine P$$b9
000157757 773__ $$0PERI:(DE-600)1474117-9$$a10.1093/brain/awaa413$$gVol. 144, no. 3, p. 999 - 1012$$n3$$p999 - 1012$$tBrain$$v144$$x1460-2156$$y2021
000157757 909CO $$ooai:pub.dzne.de:157757$$pVDB
000157757 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)2812759$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b2$$kDZNE
000157757 9131_ $$0G:(DE-HGF)POF4-352$$1G:(DE-HGF)POF4-350$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lNeurodegenerative Diseases$$vDisease Mechanisms$$x0
000157757 9141_ $$y2021
000157757 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2021-01-29
000157757 915__ $$0StatID:(DE-HGF)1190$$2StatID$$aDBCoverage$$bBiological Abstracts$$d2021-01-29
000157757 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2021-01-29
000157757 915__ $$0StatID:(DE-HGF)0420$$2StatID$$aNationallizenz$$d2022-11-09$$wger
000157757 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2022-11-09
000157757 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2022-11-09
000157757 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2022-11-09
000157757 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2022-11-09
000157757 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews$$d2022-11-09
000157757 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine$$d2022-11-09
000157757 915__ $$0StatID:(DE-HGF)1030$$2StatID$$aDBCoverage$$bCurrent Contents - Life Sciences$$d2022-11-09
000157757 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bBRAIN : 2021$$d2022-11-09
000157757 915__ $$0StatID:(DE-HGF)0600$$2StatID$$aDBCoverage$$bEbsco Academic Search$$d2022-11-09
000157757 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bASC$$d2022-11-09
000157757 915__ $$0StatID:(DE-HGF)9915$$2StatID$$aIF >= 15$$bBRAIN : 2021$$d2022-11-09
000157757 9201_ $$0I:(DE-2719)1110007$$kAG Haass old$$lALS, FTLD and Zebrafish models$$x0
000157757 980__ $$ajournal
000157757 980__ $$aVDB
000157757 980__ $$aI:(DE-2719)5000015
000157757 980__ $$aUNRESTRICTED